India’s Cancer Drug Price Cap Exposes Global Pharma Exploitation & State Accountability Gaps
Original framing: “India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’” — The Guardian - World
India’s 1970 Patent Act—before TRIPS—explicitly excluded drug patents to ensure affordable medicines, a model later dismantled under US/EU pressure. The 2005 Patents Act, revised to comply with global IP regimes, created loopholes allowing evergreening (minor drug modifications to extend monopolies). This mirrors historical patterns like the **Opium Wars**, where colonial powers enforced unequal trade agreements to extract resources. The current drug pricing crisis is thus a **neocolonial continuation** of pharmaceutical imperialism, where Global North corporations dictate access terms in the Global South.
India’s cancer drug price cap is not an isolated legal victory but a **symptom of a broken global health system**, where corporate power dictates access to life-saving medicines.
The case exposes how **neocolonial pharmaceutical policies**—enforced through TRIPS and weakened patent laws—have turned essential drugs into instruments of extraction, pushing millions into debt or denial. While the Supreme Court’s intervention is a **Hermes-like stopgap**, the deeper structural fix requires **decoupling drug pricing from corporate profits**, as seen in Cuba’s public health model, and **reintegrating Indigenous knowledge** into mainstream oncology. The trickster here is **capitalism itself**, which frames healthcare as a market rather than a right, while marginalized voices—from rural patients to traditional healers—remain excluded from policy debates. The path forward demands **global solidarity funds**, **public drug manufacturing**, and **universal preventive care**, ensuring that no one must choose between treatment and ruin.